BioSpace News Archive

According to Vision Research Reports, the e-clinical solutions market size is expected to hit around US$ 22.7 billion by 2030 and is projected to grow at a registered CAGR of 13.7% during forecast period 2021 to 2030.

According to Vision Research Reports, the non-alcoholic steatohepatitis clinical trials market size is predicted to hit around USD 4.1 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.

Pressure BioSciences, Inc. announced that Emerging Technology Insider, a leading global source for business and financial opportunities of technology companies, has released a new TechTalks video interview featuring Richard T. Schumacher, CEO and Founder of Pressure BioSciences, Inc.

According to Vision Research Reports, the eHealth market size is expected to hit around US$ 690 billion by 2030 and is anticipated to grow at a CAGR of 16.2% from 2021 to 2030.

Clinical flow cytometry laboratories based in Europe can now purchase Cytek cFluor® CE-IVD-certified reagents for their use. Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a series of single-color cFluor reagents and a 6-color TBNK kit have received CE Marking under the European Union In Vitro Diagnostic Medical Devices Directive (IVDD) 98/79/EC.

ExoCel Bio™, a biotechnology company focused on the research and development of cell-based technology, is revolutionizing the regenerative aesthetics industry with Exovex™, an all-natural serum of high quality, high concentration, non-lyophilized and purified exosomes formulated to accelerate recovery time, reduce inflammation and enhance the results of aesthetic medical treatments.

B dot Medical Inc. and Research Center for Nuclear Physics, Osaka University have conducted a Proof of Concept of the ultra-compact proton therapy system under development and confirmed that the proton beam generated by an accelerator was bent inside the superconducting bending magnet in the system and irradiated to the isocenter.

According to Vision Research Reports, the clinical trials market size is projected to reach around US$ 75 billion by 2030 from US$ 48 billion in 2020 with a CAGR of 6% during forecast period 2022 to 2030.

Alzinova AB announces the initiation of the next step in the preclinical development of its oligomer-specific monoclonal antibody, ALZ-201.

The Clinical Trial Biorepository & Archiving Solutions market size is expected to hit around US$ 10.1 billion by 2030 and is anticipated to grow at a CAGR of 15.2% during forecast period 2021 to 2030.